Indee Labs
YC W17 ↗San Francisco, US · Founded 2015 · 5 employees · 2 known investors
Indee Labs develops Hydropore™, a non-viral microfluidic technology for delivering molecules, nucleic acids, proteins, and gene-editing complexes into immune cells for engineered cell therapy research and manufacturing. The platform enables rapid production of high-quality T-cell immunotherapies and other cell therapies with preserved cell function.
BiotechDeep TechHealthtechMedical DevicesGene TherapyMicrofluidicsCell Therapyin /indee-/@indeelabsycombinator.com ↗
Founders & leadership· Y Combinator alumni (W17)
Investors · 2
In the news
- Indee Labs Announces Strategic Investment from BroadOak BioTools Venture Fundprnewswire.com · 2023
- Indee Labs Awarded $2M Contract to Scale up and out Hydropore for Cell Therapy — Indee Labsindeelabs.com · 2022
- Indee Labs Raises US$2.6M in Further Seed Financing - FinSMEsfinsmes.com · 2018
- Startup Indee Labs raises $2.6 M in seed fundingbiospectrumasia.com